2nd Department of Medicine, Medical University of Vienna, Vienna, Austria.
Ann Rheum Dis. 2013 Jan;72(1):3-6. doi: 10.1136/annrheumdis-2012-202361. Epub 2012 Nov 7.
In this viewpoint, we summarise three different lines of evidence suggesting that current biological therapies directed at different molecules or cells have similar efficacy in rheumatoid arthritis and target similar populations of patients; therefore, distinct biological effects of targeted therapies may not account for differences in response. Moreover, currently available individual biomarkers or multiple biomarker sets do not provide information beyond that conveyed by clinical disease activity. Smart and novel research designs will have to be developed to find pertinent biomarkers. Until then, the focus of clinicians may have to solely rest on clinical disease activity assessment and targeting remission or low disease activity rapidly.
在这个观点中，我们总结了三条不同的证据线，表明目前针对不同分子或细胞的生物疗法在类风湿关节炎中具有相似的疗效，并针对相似的患者群体；因此，靶向治疗的不同生物学效应可能不能解释反应的差异。此外，目前可用的单个生物标志物或多个生物标志物集并不能提供超出临床疾病活动所传达的信息。必须开发智能和新颖的研究设计来寻找相关的生物标志物。在那之前，临床医生的关注点可能必须仅仅集中在临床疾病活动评估和快速实现缓解或低疾病活动上。
